Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TTRXQ Revoked SEC
http://www.sec.gov/litigation/admin/2014/34-71321.pdf
They have an innovative drug, but some cash problems. If I read the sec filings correctly, the patents expire on their depression drug, so if they want the patents extended, they'll have to find some cash and do some quick clinical trials.
They recently settled w/ one of their creditors, but I'm not sure if there are more creditors remaining or not.
CAMARO; Is this an anti-depresent drug innovator co? Less than 1 million market capital.. Do they have any cash? cash burning rate? Holders etc? sorry, heard first time!
tia
GL
Called the company several times today... No answer.
GLTA.
About Nemifitide (from co. website):
Early pre-clinical animal studies demonstrated the powerful potential of nemifitide as a treatment for patients suffering from depression. These pre-clinical results have been confirmed by the clinical studies that we have conducted on over 400 individuals who have received nemifitide to date.
In double-blinded placebo controlled trials, nemifitide has demonstrated strong eveidence of efficacy in depressed patients. The clinical profile included a more robust and rapid onset of action with long duration and minimal adverse side effects. Extensive testing over the last ten years has demonstrated that nemifitide has distinct advantages over other drugs currently marketed to treat depression.
Rapid onset of action and symptomatic relief.The initial effects of nemifitide are observable in the first three to five days of treatment. Peak effects occur within one to two weeks, versus four to eight weeks for currently available antidepressants. Nemifitide may be used for severely depressed patients who require rapid symptomatic relief, as effectiveness can be clinically measured within 3-5 days of initiating treatment.
Little or no side effects. Nemifitide, to date, has been administered to over 400 patients and volunteers with only one patient discontinuing treatment due to side effects. This is in marked contrast to all other currently available antidepressants, which often cause short and long-term side effects frequently resulting in the premature discontinuation of treatment.
Many patients experience complete symptomatic relief. Many patients who respond to nemifitide enter into complete remission from their depression, as opposed to simply experiencing some improvement in their condition.
Potential to treat severely refractory patients. Preliminary results from an open-label pilot study (a clinical trial without the use of a placebo) in severely refractory patients(patients who have not responded to several classes of antidepressant therapy over long periods of time) have shown a response rate of over 40%. This generated a considerable amount of interest in the scientific community and, we believe, this could give nemifitide a novel role in treating this debilitating illness. It is estimated that approximately 5% to 10% of patients suffering from major depression have the refractory form of the illness.
Freedom from regular daily treatment. Because nemifitide is administered via ten to fifteen subcutaneous or needleless injections over a two to three week period, and has a long duration of effective action, it allows for intermittent clinical treatment (every four to six months) versus the chronic daily dosing required with most existing antidepressant medications. This may result in dramatically improved patient complience.
Potential to treat other CNS disorders. In addition to treating major depression, nemifitide and other patented peptides we intend to develop may be effective in the treatment of mild depression, anxiety disorders, as well as other central nervous system disorders such as anorexia, bulimia, panic disorder and post-traumatic stress disorder.
Potential for alternative forms of administration. Preliminary evidence indicates that nemifitide may be administered through needleless injections. We also intend to explore other forms of delivery, including a transdermal patch (through the skin by way of a patch) as well as nasal inhilation.
Little or no potential for adverse reactions with other drugs. Based on studies conducted to date, nemifitide is not expected to show significant drug-drug interaction in human beings. This is especially beneficial in the treatment in the geriatric population and cardiac patients with depression.
We believe nemifitide has the potential to revolutionize the antidepressant market. Antidepressant sales constitute the largest segment of the CNS market, approximately 24%. In 2004, global sales of antidepressant agents exceeded $15 billion. Based on the sales of other antidepressants, we believe that nemifitide, properly marketed, has the potential to become the treatment of choice for depression and to capture a substantial portion of the worldwide market after commercialization.
New SEC Filing on Jan. 20th!!!
http://sec.gov/Archives/edgar/data/1362659/000109690610000064/0001096906-10-000064-index.htm
GLTA.
LOL! Did not know this one!! lol
Something else interesting from the last 10Q:
4. STOCK OPTIONS
On December 31, 2008 a total of 40,000 options were granted to Bruce Bergman, Aaron Cohen, William Comer and Alf Akerman (10,000 each) for participation on board committees exercisable at $1 per share expiring 10 years from issuance. Expenses totaling $1,600 were charged to “Board Expense” in 2008.
All options are vested immediately. The options are not actively trading and the fair market value is not readily ascertainable, the options are taxable at the time of exercise as opposed to the time of their grant.
The following table presents information regarding weighted-average exercise price and weighted average remaining contractual life as of September 30, 2009.
Options Outstanding and Exercisable
Range of
Exercise Price
$1.00
Number of
Options
11,838,253
Weighted Average
Exercise Price
$1.00
Weighted Average
Remaining Life
9.1
________________________________________________________
If the company was going nowhere, then why would they issue options to their board members for $1/sh exercise price?
jmo.
GLTA.
I'm going to call the company in the morning, and see what's going on... Will repost what I hear (if they answer their phone)...
GLTA.
I like the low shares o/s here w/ TTRX... Some positive news could send it flying, imo.
GLTA.
Could be big if they could get a licensing partner...
From the last 10Q:
Management intends to find a licensing partner to continue our development of Nemifitide, primarily in treatment-resistant patients which currently represents approximately 5 to 10 percent of the overall patient population suffering from the disease. Additionally, management intends to obtain regulatory approval to sell Nemifitide in foreign jurisdictions which management believes will lead to revenue generation. We can offer no assurance that we will be successful in identifying a licensing partner or obtaining regulatory approval in the United States or any foreign jurisdiction.
GLTA.
On watch, however little volume...
so, just a watch, maybe taken off, maybe not...too many others with higher priority... for now.
just an update, have a look at historical vol...no liquidity...
http://ih.advfn.com/p.php?pid=historical&cb=1259026628&symbol=TTRX
http://www.reportlinker.com/p0160692/Tetragenex-Pharmaceuticals-Inc-Detailed-Product-Pipeline.html?request=news#utm_source=LivePR&utm_medium=pr&utm_campaign=LivePR
the report costs $750. dated september 2009
okay, will start my first assignment tonight...see what I dig up.
Drafted as i need all the help I can get. LOL got you also Z
Tetragenex Pharmaceuticals, Inc. (TTRX) | Show iBox | TTRX Quote, News, Charts Board Search: 2009 2008 2007 2006 2005 2004 2003+
Moderator: aliangel Assistants: Zorro, roach4091, pmlg
They were never in BK. The court denied their petition.
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6881343
The cash is a little low on the 10q but they also have not issued any stock lately. I have to look at the drug pipeline to see if any have any value or what phase they are in.
>>> They also have been removed from BK
This is why i'm digging a bit more
Could be a nice play !
They also have been removed from BK so this could get interesting but will do more digging. I have to tear apart there 10q now.
TETRAGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 333-134987 22-3781895
(State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification No.)
560 SYLVAN AVENUE, 3 RD FLOOR
ENGLEWOOD CLIFFS, NJ 07632
(Address of principal executive offices and Zip Code)
(201) 408-5335
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
INFORMATION ABOUT FORWARD-LOOKING STATEMENTS
Item 1.03 Bankruptcy or Receivership
As previously disclosed by Tetragenex Pharmaceuticals, Inc. (the “Company”), in the Company’s Form 10-Q for the quarter ended June 30, 2009, filed with the Securities and Exchange Commission on August 13, 2009, on August 10, 2009 the Company filed for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of New Jersey (the “Bankruptcy Court”), Case No. 09-30775.
On November 2, 2009, the Company received notice that the Bankruptcy Court dismissed its request for relief under Chapter 11 of the Bankruptcy Code (the “Order”).
The foregoing summary of the Order is qualified in its entirety by reference to the definitive court documents, copies of which are attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1 Order from the United States Bankruptcy Court District of New Jersey, dated November 2, 2009.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TETRAGENX PHARMACEUTICALS, INC.
/s/ Martin F. Schacker
Martin F. Schacker
Co-Chief Executive
Will do Dave !
Dan
Thanks we are just awaiting the filings and finding info. It does look like a solid chance of a company though. If you find anything let us know and we will do the same.
Dave
got a couple more coming also.
lol! Thanks
Drafted by default. lol
Tetragenex Pharmaceuticals, Inc. (TTRX) | Show iBox | TTRX Quote, News, Charts Board Search: 2009 2008 2007 2006 2005 2004 2003+
Moderator: aliangel Assistants: roach4091
I know! Too many to watch
Man I am watching so many right now. lol Here is just the short list. lol
Board Name Total Posts Latest Post
Tetragenex Pharmaceuticals, Inc. (TTRX) 3 11/13/2009 10:02:56 PM
CDSS Wind Down, Inc. (CWDW) 1875 11/13/2009 9:38:15 PM
CareAdvantage, Inc. (CADV) 228 11/13/2009 9:17:31 PM
Conversion Services International, Inc. (CVNS) 1 11/13/2009 1:46:16 PM
China Renewable Energy Holdings, Inc. (CREO) 0 11/13/2009 1:19:34 PM
BONANZA OIL & GAS (BGOI) 16 11/10/2009 6:25:19 PM
Advanced Medical Institute, Inc. (AVMDE) 4 11/10/2009 6:21:43 PM
Franklin Towers Enterprises, Inc. (FRTW) 123 11/9/2009 7:33:16 PM
THE WAVE (WAVERIDER) 61 11/8/2009 8:30:06 PM
PI Services, Inc. (PISV) 4 11/7/2009 8:49:13 PM
Modern Medical Modalities Corp. (MODM) 5 11/7/2009 3:20:48 PM
AE Biofuels, Inc. (AEBF) 26 11/7/2009 1:57:04 PM
Trycera Financial, Inc (USBB:TRYF) 412 11/6/2009 7:24:28 PM
Dragon International Group Corp (DRGG) 167 11/4/2009 3:15:06 PM
China Health Resource, Inc. (CHRI) 141 11/3/2009 1:45:18 PM
CHINA BROADBAND (CBBD) 13 11/2/2009 7:21:21 PM
Bigstring Corp. (BSGC) 269 10/16/2009 2:06:11 PM
BrookMount Exploration Inc. (BMXI) 10 10/15/2009 4:42:17 PM
Robocom Systems International Inc. (RIMS) 22 10/15/2009 3:30:51 PM
Dynasty Energy Resources, Inc. (DYER) 135 10/13/2009 11:26:31 AM
Saker Aviation Services Inc. (SKAS) 10 10/4/2009 9:48:57 PM
Boards Assisted By aliangel
Board Name Total Posts Latest Post
Ruby Creek Resources, Inc. (RBYC) 24 11/13/2009 10:03:30 PM
OTCBB ALERTS 284549 11/13/2009 9:16:53 PM
Green Planet Group, Inc. (GNPG) 1175 11/13/2009 6:23:33 PM
LIZZY & WIZZY''S PINK & OTC 100%+ gainers 8089 11/13/2009 5:05:51 PM
WINGS 158 11/13/2009 4:35:48 PM
Wavelit (WAVL)
Just started the board today. Not sure yet.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
40
|
Created
|
11/13/09
|
Type
|
Free
|
Moderators |
www.tetragenex.com
Who is Tetragenex Pharmaceuticals?
Tetragenex Pharmaceuticals, Inc. (formerly Innapharma, Inc.) is a publicly held biopharmaceutical company working to discover, develop and commercialize proprietary pharmaceutical products that treat serious diseases for which current therapies are inadequate. We have synthesized and patented a novel platform of pharmaceutical “small chain” peptides that treat depression, and may treat anxiety and other central nervous system disorders. Our leading product candidate is the antidepressant compound nemifitide, is in advanced, late Phase II, human clinical trials.
The Company, has also synthesized and is developing a platform of new and unique chemically-modified tetracycline molecules to be used in the treatment of certain types of cancer and antibiotic-resistant bacterial infections. These tetracycline-based product candidates are in the pre-clinical development stage.
Our objective is to license our platform of CNS compounds to a pharmaceutical company that is capable of completing the development and eventually distributing these compounds once they are registered. As we proceed on this front we will continue the expansion of our clinical program.
We intend to expand our scientific staff and attempt to become a fully integrated pharmaceutical company, primarily through our expertise in the identification, acquisition, and development of pharmaceutical products and technologies.
What are some of the details on "Nemifitide"?
Early pre-clinical animal studies demonstrated the powerful potential of nemifitide as a treatment for patients suffering from depression. These pre-clinical results have been confirmed by the clinical studies that we have conducted on over 400 individuals who have received nemifitide to date.
In double-blinded placebo controlled trials, nemifitide has demonstrated strong eveidence of efficacy in depressed patients. The clinical profile included a more robust and rapid onset of action with long duration and minimal adverse side effects. Extensive testing over the last ten years has demonstrated that nemifitide has distinct advantages over other drugs currently marketed to treat depression.
Rapid onset of action and symptomatic relief.The initial effects of nemifitide are observable in the first three to five days of treatment. Peak effects occur within one to two weeks, versus four to eight weeks for currently available antidepressants. Nemifitide may be used for severely depressed patients who require rapid symptomatic relief, as effectiveness can be clinically measured within 3-5 days of initiating treatment.
Little or no side effects. Nemifitide, to date, has been administered to over 400 patients and volunteers with only one patient discontinuing treatment due to side effects. This is in marked contrast to all other currently available antidepressants, which often cause short and long-term side effects frequently resulting in the premature discontinuation of treatment.
Many patients experience complete symptomatic relief. Many patients who respond to nemifitide enter into complete remission from their depression, as opposed to simply experiencing some improvement in their condition.
Potential to treat severely refractory patients. Preliminary results from an open-label pilot study (a clinical trial without the use of a placebo) in severely refractory patients(patients who have not responded to several classes of antidepressant therapy over long periods of time) have shown a response rate of over 40%. This generated a considerable amount of interest in the scientific community and, we believe, this could give nemifitide a novel role in treating this debilitating illness. It is estimated that approximately 5% to 10% of patients suffering from major depression have the refractory form of the illness.
Freedom from regular daily treatment. Because nemifitide is administered via ten to fifteen subcutaneous or needleless injections over a two to three week period, and has a long duration of effective action, it allows for intermittent clinical treatment (every four to six months) versus the chronic daily dosing required with most existing antidepressant medications. This may result in dramatically improved patient complience.
Potential to treat other CNS disorders. In addition to treating major depression, nemifitide and other patented peptides we intend to develop may be effective in the treatment of mild depression, anxiety disorders, as well as other central nervous system disorders such as anorexia, bulimia, panic disorder and post-traumatic stress disorder.
Potential for alternative forms of administration. Preliminary evidence indicates that nemifitide may be administered through needleless injections. We also intend to explore other forms of delivery, including a transdermal patch (through the skin by way of a patch) as well as nasal inhilation.
Little or no potential for adverse reactions with other drugs. Based on studies conducted to date, nemifitide is not expected to show significant drug-drug interaction in human beings. This is especially beneficial in the treatment in the geriatric population and cardiac patients with depression.
We believe nemifitide has the potential to revolutionize the antidepressant market. Antidepressant sales constitute the largest segment of the CNS market, approximately 24%. In 2004, global sales of antidepressant agents exceeded $15 billion. Based on the sales of other antidepressants, we believe that nemifitide, properly marketed, has the potential to become the treatment of choice for depression and to capture a substantial portion of the worldwide market after commercialization.
In addition, Tetragenex Pharmaceuticals Inc. continues to synthesize and test compounds in its platform of small peptides. To date, we have evaluated more than 200 of these compounds, and our efforts are ongoing. This work has already identified several drug candidates that are believed to show even greater activity in pre-clinical testing than nemifitide, and these compounds have been designated as potential second-generation drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |